PILOT STUDY FOR IDENTIFYING URINARY PROSTATE CANCER BIOMARKERS

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 尿前列腺癌蛋白生物标志物对于早期癌症检测是重要的。 在这一点上进行尿检可以显着减少由于血清PSA升高而进行的不必要的活检数量。 基因组学在癌细胞中的应用已经允许鉴定许多候选生物标志物以供进一步研究。 这项初步研究将利用先进的靶向蛋白质组学技术，使用资源中心的多反应监测（MRM）来测试尿液样本中已鉴定的癌症蛋白质的区分能力。 预计该应用程序还将推动目标MRM技术的进一步开发和优化。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Urinary prostate cancer protein biomarkers are important for early cancer detection. A urine test at this point can significantly reduce the number of unnecessary biopsies done as a result of elevated serum PSA. The application of genomics to cancer cells has allowed the identification of a number of candidate biomarkers for further investigations. This pilot study will utilize the advanced targeted proteomic technology using multiple reaction monitoring (MRM) under the resource center for testing the discriminatory power of identified cancer proteins in urine samples. The application is also anticipated to drive further development and optimization of the targeted MRM technology.